Myelofibrosis

Myelofibrosis (MF) is a rare blood cancer that leads to scarring in the bone marrow, which prevents the normal production of blood cells. The condition is a primary subtype of myeloproliferative neoplasms (MPNs) and, in some cases, start as another MPN, like polycythemia vera (PV) or essential thrombocythemia (ET), and later evolve into myelofibrosis.

Cecilia BrownMyelofibrosis | March 21, 2023
Hematopoietic stem/progenitor cells from patients with myelofibrosis are “enriched” for a CXCL8/CXCR2 gene signature.
Read More
Cecilia BrownMyelofibrosis | March 16, 2023
A reduction in spleen volume reduction of ≥35% at 24 weeks occurred in 68% of patients.
Cecilia BrownMyelofibrosis | February 8, 2023
The study’s investigators are continuing to monitor overall survival and conduct ongoing patient follow-up.
Cecilia BrownMyelofibrosis | January 24, 2023
The overall risk of death from primary myelofibrosis declined by more than 50% after the U.S. FDA approved ruxolitinib.
Kerri FitzgeraldMeeting News | December 19, 2022
Mutation of CALR in patients with myelofibrosis may be associated with a more anemic phenotype at diagnosis.
Leah SherwoodMeeting News | December 13, 2022
John Mascarenhas, MD, discusses the results of the PACIFICA trial at the 2022 American Society of Hematology Annual Meeting.
Keightley AmenMeeting News | December 12, 2022
Parsaclisib plus ruxolitinib can improve symptoms and spleen volume in certain patients with myelofibrosis.
Keightley AmenMyelofibrosis | December 10, 2022
TP53 and complex karyotype are very high-risk factors in patients with myelofibrosis undergoing HSCT.
Keightley AmenMyelofibrosis | December 10, 2022
The combination of ruxolitinib and pegylated IFNα2a showed significant reductions in spleen length.
Keightley AmenMeeting News | December 10, 2022
BMS-986158 combined with ruxolitinib or fedratinib reduced spleen volume in patients with myelofibrosis.
Kerri FitzgeraldMyeloproliferative Neoplasms | December 10, 2022
Selinexor plus ruxolitinib demonstrated promising clinical activity in patients with treatment-naïve myelofibrosis.
Kerri FitzgeraldMyeloproliferative Neoplasms | December 10, 2022
Momelotinib led to an increased likelihood of becoming transfusion-independent compared with danazol in myelofibrosis.
Cecilia BrownMyelodysplastic Syndromes | December 7, 2022
Findings from a new study “underscore the limited therapeutic value of luspatercept” in anemia and myelofibrosis.
Leah SherwoodMyeloproliferative Neoplasms | November 29, 2022
Those with MF with high molecular and cytogenetic risk do not benefit from higher intensity conditioning before transplant.
Cecilia BrownMyeloproliferative Neoplasms | November 16, 2022
Adding navitoclax to ruxolitinib led to durable spleen volume reductions and improved total symptoms in myelofibrosis.
Cecilia BrownMyeloproliferative Neoplasms | November 16, 2022
There are several risk factors for thrombosis and major bleeding in patients with myelofibrosis, according to a recent study.
Leah SherwoodMyeloproliferative Neoplasms | October 28, 2022
A large analysis of real-world treatment outcomes in patients with myelofibrosis who were treated with ruxolitinib.
Leah SherwoodMyeloproliferative Neoplasms | October 28, 2022
Momelotinib led to “superior” symptom and spleen responses and transfusion independence rates compared to danazol.
Kerri FitzgeraldMyeloproliferative Neoplasms | October 20, 2022
A recent case study found evidence of an acquired in utero mutation in monozygotic twins who presented with CALR.
Kerri FitzgeraldMyeloproliferative Neoplasms | October 20, 2022
A new prognostic model identified risk factors for reduced survival in patients with myelofibrosis who received ruxolitinib.
Kerri FitzgeraldMyeloproliferative Neoplasms | October 20, 2022
The EXPAND study supports the use of ruxolitinib 10 mg twice daily in patients with MF.
Leah SherwoodMyeloproliferative Neoplasms | October 12, 2022
A retrospective study observed a three-year OS rate of 66.7% in primary MF patients and 55.6% in secondary MF patients...
Leah SherwoodTransplantation & Cellular Therapy | July 20, 2022
The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application from Cellenkos, Inc. to ...
Leah LawrenceMyelofibrosis | June 8, 2022
The REFINE trial observed clinically meaningful splenic responses with navitoclax plus ruxolitinib.
Leah LawrenceMyeloproliferative Neoplasms | May 26, 2022
Tasquinimod is an oral immunomodulatory and antiangiogenic investigational treatment.
Ariel DeMaioPrint | May 4, 2022
In patients with persistent or progressive myelofibrosis, adding the BCL-XL/BCL-2 inhibitor navitoclax to therapy with the ...
Sabrina AhleMyeloproliferative Neoplasms | March 12, 2022
The FDA has granted accelerated approval to pacritinib for the treatment of adult patients with intermediate or high-risk.
Helen T. Chifotides, PhDMyeloproliferative Neoplasms | January 21, 2022
Experts discuss emerging therapeutic targets, the impact of recently approved agents, and incorporating them into practice.
Advertisement
Advertisement
Advertisement
Advertisement
Latest News

March 24, 2023